CureDuchenne is proud to sponsor SB 643 (Pan). SB 643 will add Duchenne to the Genetically Handicapped Persons Program’s (GHPP) list of eligible medical conditions. Duchenne is a rare neuromuscular […]
We are happy to share the following letter to the Duchenne Community from Stu Peltz, CEO PTC Therapeutics. March 24, 2017 Dear Duchenne Community, We were very excited to […]
If you told someone your child had cancer, they would immediately have a sense of the disease and potentially even a sense of the treatment options. People know about chemo, […]
Haydee Bustos has a passion for helping kids, and through her experience as a physical therapist, she discovered an even deeper desire to help kids with Duchenne muscular dystrophy. […]
CureDuchenne is sharing an expanded and updated open letter to the Duchenne community from Marathon Pharmaceuticals. An Open Letter to the Duchenne Community Dear Members of the Duchenne Community: […]
CureDuchenne is sharing an expanded and updated open letter to the Duchenne community from Marathon Pharmaceuticals. An Open Letter to the Duchenne Community Dear Members of the Duchenne Community: […]
We are delighted that the U.S. Food and Drug Administration (FDA) has approved EMFLAZA (deflazacort) for the treatment of Duchenne. This is wonderful news for the Duchenne community to […]
Today, the FDA approved the use of EMFLAZA (deflazacort) for Duchenne patients over the age of five years old. It is routine for the FDA to designate specific patient […]
The MoveDMD trial with edasalonexent (CAT-1004) in Duchenne muscular dystrophy (DMD) has just completed Part B, and Catabasis has released the top-line results. Summary: The top-line results that […]
